The complement cascade and renal disease

Archivum Immunologiae et Therapiae Experimentalis

Volumn 62, Issue 1, 2014, Pages 47-57

  Koåcielska Kasprzak, Katarzyna ^a   Bartoszek, Dorota ^a   Myszka, Marta ^a   Åabińska, Marcelina ^a   Klinger, Marian ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Complement cascade; Kidney injury; Renal disease

Indexed keywords

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; BASEMENT MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; ISOANTIBODIES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION;

EID: 84895067172     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-013-0254-x     Document Type: Review

References (109)

1. Appel GB, Cook HT et al (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16:1392-1403
2. Beck LH Jr, Salant DJ (2010) Membranous nephropathy: recent travels and new roads ahead. Kid Int 77:765-770
3. Besbas N, Karpman D et al (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kid Int 70:423-431
4. Bexborn F, Andersson PO et al (2008) The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol 45:2370-2379
5. Bienaime F, Dragon-Durey MA et al (2009) Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kid Int 77:339-349
6. Bijl M, Limburg PC et al (2001) New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. Neth J Med 59:66-75
7. Boij R, Svensson J et al (2012) Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 68:258-270
8. Bomback AS, Smith RJ et al (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7:748-756
9. Burwick RM, Feinberg BB (2013) Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 34:201-203
10. Buurma A, Cohen D et al (2012) Preeclampsia is characterized by placental complement dysregulation. Hypertension 60:1332-1337
11. Chen M, Xing GQ et al (2009) Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transpl 24:1247-1252
12. Chen M, Daha MR et al (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276-J286
13. Chen Q, Muller D et al (2011) Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365:2340-2342
14. D'Agati VD, Bomback AS (2012) C3 glomerulopathy: what's in a name? Kid Int 82:379-381
15. Damman J, Nijboer WN et al (2010) Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transpl 26:2345-2354
16. Damman J, Daha MR et al (2011) Crosstalk between complement and toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transpl 11:660-669
17. DeAngelis RA, Reis ES et al (2012) Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 217:1097-1105
18. Delvaeye M, Noris M et al (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361:345-357
19. Denny KJ, Woodruff TM et al (2012) Complement in pregnancy: a delicate balance. Am J Reprod Immunol 69:3-11
20. Derzsy Z, Prohaszka Z et al (2010) Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 47:1500-1506
21. Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330:565
22. Espinosa M, Ortega R et al (2009) Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transpl 24:886-891
23. Feucht HE, Schneeberger H et al (1993) Capillary deposition of C4d complement fragment and early renal graft loss. Kid Int 43:1333-1338
24. Foster MH (2008) Novel targets for immunotherapy in glomerulonephritis. Biologics 2:531-545
25. Gharavi AG, Kiryluk K et al (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321-327
26. Glesse N, Monticielo OA et al (2011) Association of mannose-binding lectin 2 gene polymorphic variants with susceptibility and clinical progression in systemic lupus erythematosus. Clin Exp Rheumatol 29:983-990
27. Gonzalez-Roncero F, Suner M et al (2012) Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transpl Proc 44:2690-2694
28. Goodship TH, Pappworth IY et al (2012) Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 52:200-206
29. Haidar F, Kisserli A et al (2012) Comparison of C4d detection on erythrocytes and PTC-C4d to histological signs of antibody-mediated rejection in kidney transplantation. Am J Transpl 12:1564-1575
30. Herlitz LC, Bomback AS et al (2012) Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 23:1229-1237
31. Hirt-Minkowski P, Dickenmann M et al (2010) Atypical hemolytic uremic syndrome: update on the complement system and what is new. Nephron Clin Pract 114:c219-c235
32. Hisano S, Matsushita M et al (2001) Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kid Dis 38:1082-1088
33. Hisano S, Matsushita M et al (2005) Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis. Am J Kid Dis 45:295-302
34. Hudson BG, Tryggvason K et al (2003) Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348:2543-2556
35. Iida K, Mornaghi R et al (1982) Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 155:1427-1438
36. Kavanagh D, Goodship T (2010) Genetics and complement in atypical HUS. Pediatr Nephrol 25:2431-2442
37. Kavanagh D, Goodship TH (2011) Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program 2011:15-20
38. Kavanagh D, Richards A et al (2008) Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 45:95-105
39. Kielstein JT, Beutel G et al (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transpl 27:3807-3815
40. Klos A, Tenner AJ et al (2009) The role of the anaphylatoxins in health and disease. Mol Immunol 46:2753-2766
41. Lalli PN, Strainic MG et al (2008) Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112:1759-1766
42. Lapeyraque AL, Malina M et al (2011) Eculizumab in severe shiga-toxin-associated HUS. N Engl J Med 364:2561-2563
43. Lee YH, Witte T et al (2005) The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 52:3966-3974
44. Lemaire M, Fremeaux-Bacchi V et al (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531-536
45. Lhotta K, Wurzner R et al (1999) Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transpl 14:881-886
46. Li K, Patel H et al (2004) Complement activation regulates the capacity of proximal tubular epithelial cell to stimulate alloreactive T cell response. J Am Soc Nephrol 15:2414-2422
47. Licht C, Fremeaux-Bacchi V (2009) Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis. Thromb Haemost 101:271-278
48. Loirat C, Fremeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60
49. Loirat C, Noris M et al (2008) Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 23:1957-1972
50. Loirat C, Saland J et al (2012) Management of hemolytic uremic syndrome. Presse Med 41(3 Pt 2):e115-e135
51. Lynch AM, Murphy JR et al (2008) Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 198(385):e1-e9
52. Ma R, Cui Z et al (2013) Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease. J Clin Immunol 33:172-178
53. Maga TK, Nishimura CJ et al (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:E1445-E1460
54. Malina M, Roumenina LT et al (2012) Genetics of hemolytic uremic syndromes. Presse Med 41(3 Pt 2):e105-e114
55. Marks SD, Tullus K (2011) Autoantibodies in systemic lupus erythematosus. Pediatr Nephrol 27:1855-1868
56. Meszaros T, Fust G et al (2010) C1-inhibitor autoantibodies in SLE. Lupus 19:634-638
57. Mok MY, Jack DL et al (2004) Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. Lupus 13:522-528
58. Moller-Kristensen M, Wang W et al (2005) Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol 61:426-434
59. Monte S (2011) Biochemical markers for prediction of preclampsia: review of the literature. J Prenat Med 5:69-77
60. Moore I, Strain L et al (2010) Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115:379-387
61. Nataf S, Davoust N et al (1999) Human T cells express the C5a receptor and are chemo-attracted to C5a. J Immunol 162:4018-4023
62. Nester C, Stewart Z et al (2011) Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6:1488-1494
63. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676-1687
64. Nurnberger J, Philipp T et al (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542-544
65. Parker CJ, Kar S et al (2007) Eculizumab. Nat Rev Drug Discov 6:515-516
66. Peng Q, Li K et al (2006) Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 176:3330-3341
67. Pennington KA, Schlitt JM et al (2012) Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech 5:9-18
68. Pradhan V, Mahant G et al (2013) A study on anti-mannose binding lectin (anti-MBL) antibodies and serum MBL levels in Indian systemic lupus erythematosus patients. Rheumatol Int 33:1193-1199
69. Pratschke J, Wilhelm MJ et al (2000) Accelerated rejection of renal allografts from brain-dead donors. Ann Surg 232:263-271
70. Pratschke J, Wilhelm MJ et al (2001) Influence of donor brain death on chronic rejection of renal transplants in rats. J Am Soc Nephrol 12:2474-2481
71. Pratt JR, Abe K et al (2000) In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am J Pathol 157:825-831
72. Pratt JR, Basheer SA et al (2002) Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8:582-587
73. Provaznikova D, Rittich S et al (2012) Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol 27:73-81
74. Qing X, Redecha PB et al (2011) Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kid Int 79:331-339
75. Roumenina LT, Loirat C et al (2011) Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 365:8-26
76. Sacks S, Zhou W (2008) New boundaries for complement in renal disease. J Am Soc Nephrol 19:1865-1869
77. Sacks S, Karegli J et al (2013) Targeting complement at the time of transplantation. Adv Exp Med Biol 734:247-255
78. Salmon JE, Heuser C et al (2011) Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 8:e1001013
79. Sandrin-Garcia P, Brandao LA et al (2011) Mannose binding lectin gene (MBL2) functional polymorphisms are associated with systemic lupus erythematosus in southern Brazilians. Hum Immunol 72:516-521
80. Sarma JV, Ward PA (2011) The complement system. Cell Tissue Res 343:227-235
81. Schraufstatter IU, Trieu K et al (2002) Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 169:2102-2110
82. Schreiber A, Xiao H et al (2009) C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20:289-298
83. Seelen MA, Trouw LA et al (2003a) Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 12:619-624
84. Seelen MA, Trouw LA et al (2003b) Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol 134:335-343
85. Sethi S, Nester CM et al (2012) Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kid Int 81:434-441
86. Shoenfeld Y, Szyper-Kravitz M et al (2007) Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann NY Acad Sci 1108:227-239
87. Sis B, Mengel M et al (2010) Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transpl 10:464-471
88. Skerka C, Jozsi M et al (2009) Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 101:227-232
89. Smith KD, Alpers CE (2005) Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens 14:396-403
90. Song D, Zhou W et al (1998) Compartmental localization of complement component transcripts in the normal human kidney. Nephron 78:15-22
91. Stegall MD, Diwan T et al (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transpl 11:2405-2413
92. Stewart ZA, Collins TE et al (2012) Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transpl Proc 44:3033-3036
93. Takada M, Nadeau KC et al (1997) The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 99:2682-2690
94. Taylor PR, Carugati A et al (2000) A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 192:359-366
95. Tedesco F, Radillo O et al (1990) Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin Exp Immunol 80:236-240
96. Tillou X, Poirier N et al (2010) Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kid Int 78:152-159
97. Trouw LA, Seelen MA et al (2004) Anti-C1q autoantibodies in murine lupus nephritis. Clin Exp Immunol 135:41-48
98. Truedsson L, Bengtsson AA et al (2007) Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40:560-566
99. Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365:2110-2121
100. Turnberg D, Cook HT (2005) Complement and glomerulonephritis: new insights. Curr Opin Nephrol Hypertens 14:223-228
101. Val-Bernal JF, Garijo MF et al (2011) C4d immunohistochemical staining is a sensitive method to confirm immuno-reactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis. Histol Histopathol 26:1391-1397
102. van der Touw W, Cravedi P et al (2013) Cutting edge: receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. J Immunol 190:5921-5925
103. Waters AM, Licht C (2011) aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 26:41-57
104. Yuan J, Gou SJ et al (2012) C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther 14:R140
105. Zhang Y, Meyer NC et al (2012) Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7:265-274
106. Zhou W, Sacks S (2006) Complement in renal transplantation. In: Zipfel PF (ed) Complement and kidney disease. Birkhäuser, Basel, pp 19-35
107. Zhou W, Patel H et al (2006) Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood 107:2461-2469
108. Zimmerhackl LB, Hofer J et al (2010) Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 362:1746-1748
109. Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729-740